Molecular rejection signals in chronic-active T cell–mediated rejection: Histological associations and potential clinical implications

Chronic-active T cell-mediated rejection (caTCMR) remains debated, and molecular diagnostics might aid risk-stratification. This retrospective two-center observational study analyzed 26 kidney allograft biopsies with caTCMR, comparing them to 40 borderline T cell-mediated rejection (bTCMR)/acute T cell-mediated rejection (aTCMR) cases (without caTCMR) and 308 subthreshold/negative controls after excluding microvascular inflammation at/above threshold and overlapping pathologies. All biopsies received transcriptomic evaluation through microarray-based gene expression profiling. caTCMR cases with aTCMR (n = 8) showed higher molecular T cell-mediated rejection (TCMR) activity (median probability of molecular TCMR [TCMR<sub>prob</sub>] 0.54 [0.30-0.83]) than "pure" caTCMR (n = 11; TCMR<sub>prob</sub> 0.03 [0.01-0.28], P = .012) or caTCMR with bTCMR (n = 7; TCMR<sub>prob</sub> 0.01 [0.01-0.77], P = .036). TCMR<sub>prob</sub> was low in subthreshold/negative controls but elevated in aTCMR, BK-virus nephropathy and pyelonephritis cases (side cohort). Molecular sign-outs classified 4 of 11 (36%) "pure" caTCMR cases as molecular TCMR. Within the TCMR continuum (26 caTCMR plus 40 bTCMR/aTCMR), interstitial inflammation, tubulitis, and total inflammation-lesions were associated in univariable analyses with TCMR<sub>prob</sub> >0.2, while interstitial inflammation in areas of interstitial fibrosis and tubular atrophy/tubulitis in areas of interstitial fibrosis and tubular atrophy correlated with molecular chronicity. Seven of 26 (27%) caTCMR and 7 of 40 (18%) bTCMR/aTCMR cases showed mixed molecular rejection activity above thresholds. In conclusion, significant molecular TCMR activity was present in a subset of caTCMR cases and was associated with higher inflammation/tubulitis/total inflammation scores and, at times, molecular antibody-mediated rejection signals, even with microvascular inflammation <2. To confirm these preliminary observations, future studies and external validation are needed.

Authors

Institutions

Publication Details

Journal
American Journal of Transplantation
Published
2026-01-01
DOI
https://doi.org/10.1016/j.ajt.2025.12.288
Primary Topic
Renal Transplantation Outcomes and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Molecular rejection signals in chronic-active T cell–mediated rejection: Histological associations and potential clinical implications

Thomas Schachtner, Luděk Voska, Kerstin Hübel, Florian Westphal et al.
American Journal of Transplantation
Renal Transplantation Outcomes and Treatments
article

Molecular rejection signals in chronic-active T cell–mediated rejection: Histological associations and potential clinical implications

Thomas Schachtner, Luděk Voska, Kerstin Hübel, Florian Westphal, Britta George, Ariana Gaspert, Ondřej Viklický, Birgit Helmchen, Lukas Weidmann, Dušan Harmáček, Eva Girmanová, Seraina von Moos, Elena Rho, Katerina Jaklova, Petra Hruba, Kai Castrezana Lopez
article en

Abstract

Chronic-active T cell-mediated rejection (caTCMR) remains debated, and molecular diagnostics might aid risk-stratification. This retrospective two-center observational study analyzed 26 kidney allograft biopsies with caTCMR, comparing them to 40 borderline T cell-mediated rejection (bTCMR)/acute T cell-mediated rejection (aTCMR) cases (without caTCMR) and 308 subthreshold/negative controls after excluding microvascular inflammation at/above threshold and overlapping pathologies. All biopsies received transcriptomic evaluation through microarray-based gene expression profiling. caTCMR cases with aTCMR (n = 8) showed higher molecular T cell-mediated rejection (TCMR) activity (median probability of molecular TCMR [TCMR<sub>prob</sub>] 0.54 [0.30-0.83]) than "pure" caTCMR (n = 11; TCMR<sub>prob</sub> 0.03 [0.01-0.28], P = .012) or caTCMR with bTCMR (n = 7; TCMR<sub>prob</sub> 0.01 [0.01-0.77], P = .036). TCMR<sub>prob</sub> was low in subthreshold/negative controls but elevated in aTCMR, BK-virus nephropathy and pyelonephritis cases (side cohort). Molecular sign-outs classified 4 of 11 (36%) "pure" caTCMR cases as molecular TCMR. Within the TCMR continuum (26 caTCMR plus 40 bTCMR/aTCMR), interstitial inflammation, tubulitis, and total inflammation-lesions were associated in univariable analyses with TCMR<sub>prob</sub> >0.2, while interstitial inflammation in areas of interstitial fibrosis and tubular atrophy/tubulitis in areas of interstitial fibrosis and tubular atrophy correlated with molecular chronicity. Seven of 26 (27%) caTCMR and 7 of 40 (18%) bTCMR/aTCMR cases showed mixed molecular rejection activity above thresholds. In conclusion, significant molecular TCMR activity was present in a subset of caTCMR cases and was associated with higher inflammation/tubulitis/total inflammation scores and, at times, molecular antibody-mediated rejection signals, even with microvascular inflammation <2. To confirm these preliminary observations, future studies and external validation are needed.

American Journal of Transplantation
University of Lucerne (CH), University Hospital of Zurich (CH), Institute of Clinical and Experimental Medicine (CZ)
Openalex Percentile: Top 98%
Renal Transplantation Outcomes and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.